AEON Biopharma (AEON) Q1 2026 earnings summary

Executive summary

• Advanced ABP-450 as a biosimilar to Botox® for therapeutic indications, targeting a $3.5B and growing market in 2026, with positive FDA Type 2a meeting feedback supporting the analytical similarity strategy under the 351(k) pathway.

• Analytical studies showed a 100% amino acid sequence match to Botox® and highly similar potency.

• Strengthened financial position by reducing outstanding debt by over 90% through PIPE financing and note exchange.

• No revenue generated to date; continued operating losses and negative cash flows expected for the foreseeable future.

• Appointment of John Bencich as CFO, bringing over 25 years of leadership experience, effective April 2026.

Financial highlights

• Net loss of $11.8M for Q1 2026, compared to net income of $9.1M in Q1 2025, driven by non-cash items and increased R&D and SG&A expenses.

• Cash and cash equivalents were $6.2M as of March 31, 2026, with an additional $0.9M received in April.

• Accumulated deficit increased to $482.6M as of March 31, 2026.

• Total assets increased to $8.6M from $5.6M at year-end 2025; total liabilities decreased to $25.4M from $60.6M.

• SG&A expenses increased 26% year-over-year to $3.9M; R&D expenses rose 150% to $2.0M.

Outlook and guidance

• Sufficient cash to fund operations into Q3 2026; additional funding required for further development and regulatory milestones.

• Plans to complete the majority of the analytical comparability program in 2026 and request a Type 2b FDA meeting in the second half of 2026.

• No expectation of product revenue until regulatory approval and commercialization.